Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Fehse

Showing results (21-30 of 49) with videos related to

Pageof 5
Sort By:
Leukemia|August 30, 2002
Persisting multilineage transgene expression in the clonal progeny of a hematopoietic stem cellZ Li, B Fehse, B Schiedlmeier, et al.
Gene Therapy|October 12, 1999
Establishment of an optimised gene transfer protocol for human primary T lymphocytes according to clinical requirementsF Ayuk, Z Li, K Kühlcke, et al.
Gene Therapy|August 24, 1999
Bicistronic retroviral vectors for combining myeloprotection with cell-surface markingM Hildinger, A Schilz, H G Eckert, et al.
Bone Marrow Transplantation|May 13, 1998
Purging and haemopoietic progenitor cell selection by CD34+ cell separationW Krüger, M Gruber, S Hennings, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 10, 2000
CD34 splice variant: an attractive marker for selection of gene-modified cellsB Fehse, A Richters, K Putimtseva-Scharf, et al.
Gene Therapy|February 3, 2007
Gene transfer of SHIP-1 inhibits proliferation of juvenile myelomonocytic leukemia cells carrying KRAS2 or PTPN11 mutationsA Metzner, M A Horstmann, B Fehse, et al.
Leukemia|March 13, 2001
The inositol 5-phosphatase SHIP is expressed as 145 and 135 kDa proteins in blood and bone marrow cells in vivo, whereas carboxyl-truncated forms of SHIP are generated by proteolytic cleavage in vitroS Horn, J Meyer, J Heukeshoven, et al.
Gene Therapy|November 17, 2017
SHIP1, but not an AML-derived SHIP1 mutant, suppresses myeloid leukemia growth in a xenotransplantation mouse modelM Täger, S Horn, E Latuske, et al.
Bone Marrow Transplantation|July 18, 2017
Impact of molecular residual disease post allografting in myelofibrosis patientsC Wolschke, A Badbaran, T Zabelina, et al.
British Journal of Haematology|August 8, 1998
Highly-efficient gene transfer with retroviral vectors into human T lymphocytes on fibronectinB Fehse, U M Schade, Z Li, et al.
Pageof 5

Showing results (21-30 of 49) with videos related to

Sort By:
Pageof 5
Leukemia|August 30, 2002
Persisting multilineage transgene expression in the clonal progeny of a hematopoietic stem cellZ Li, B Fehse, B Schiedlmeier, et al.
Gene Therapy|October 12, 1999
Establishment of an optimised gene transfer protocol for human primary T lymphocytes according to clinical requirementsF Ayuk, Z Li, K Kühlcke, et al.
Gene Therapy|August 24, 1999
Bicistronic retroviral vectors for combining myeloprotection with cell-surface markingM Hildinger, A Schilz, H G Eckert, et al.
Bone Marrow Transplantation|May 13, 1998
Purging and haemopoietic progenitor cell selection by CD34+ cell separationW Krüger, M Gruber, S Hennings, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 10, 2000
CD34 splice variant: an attractive marker for selection of gene-modified cellsB Fehse, A Richters, K Putimtseva-Scharf, et al.
Gene Therapy|February 3, 2007
Gene transfer of SHIP-1 inhibits proliferation of juvenile myelomonocytic leukemia cells carrying KRAS2 or PTPN11 mutationsA Metzner, M A Horstmann, B Fehse, et al.
Leukemia|March 13, 2001
The inositol 5-phosphatase SHIP is expressed as 145 and 135 kDa proteins in blood and bone marrow cells in vivo, whereas carboxyl-truncated forms of SHIP are generated by proteolytic cleavage in vitroS Horn, J Meyer, J Heukeshoven, et al.
Gene Therapy|November 17, 2017
SHIP1, but not an AML-derived SHIP1 mutant, suppresses myeloid leukemia growth in a xenotransplantation mouse modelM Täger, S Horn, E Latuske, et al.
Bone Marrow Transplantation|July 18, 2017
Impact of molecular residual disease post allografting in myelofibrosis patientsC Wolschke, A Badbaran, T Zabelina, et al.
British Journal of Haematology|August 8, 1998
Highly-efficient gene transfer with retroviral vectors into human T lymphocytes on fibronectinB Fehse, U M Schade, Z Li, et al.
Pageof 5